

Methods for treatment of renal failure (Technion)**code:** DRS-0764

Rasagiline is an approved anti-parkinson drug in Europe and Israel. The present invention describes in-vivo experiments demonstrating the improvement in function of hypoperfused as well as normal kidneys pretreated with Rasagiline and its derivatives. Rasagiline derivatives produce significant diuretic and natriuretic responses in association with increased GFR in rats with CHF as well as induce diuretic and natriuretic responses accompanied by improved GFR in the ischemic kidney. It is proposed that this derivative can be used for the treatment of acute and chronic kidney failure.

Contact for more information:Santiago Ini , +972-4-8294856

T - Technion Technology Transfer
Technion City, Senate Bldg., Haifa 32000, Israel
Tel. 972-4-829-4851; 972-8325-375
Fax. 972-4-832-0845